Evidence map›Paper›PMID 40969440›Full record

ArticleFrontiers in microbiology2025

Construction of an engineered

Yu Lin, Yiwei Ding, Lin Shu, Huizhen Chen, Nan Li, Xiaoqun Duan, Wei Zeng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yu Lin *Key Laboratory of Molecular Medical Engineering, Education Department of Guangxi Zhuang Autonomous Region, School of Intelligent Medicine and Biotechnology, Guilin Medical University, Guilin, China.
Yiwei Ding *College of Life Science and Technology, Guangxi University, Nanning, China.
Lin ShuKey Laboratory of Molecular Medical Engineering, Education Department of Guangxi Zhuang Autonomous Region, School of Intelligent Medicine and Biotechnology, Guilin Medical University, Guilin, China.
Huizhen ChenKey Laboratory of Molecular Medical Engineering, Education Department of Guangxi Zhuang Autonomous Region, School of Intelligent Medicine and Biotechnology, Guilin Medical University, Guilin, China.
Nan LiCollege of Life Science and Technology, Guangxi University, Nanning, China.
Xiaoqun DuanSchool of Biomedical Industry, Guilin Medical University, Guilin, China.
Wei ZengKey Laboratory of Molecular Medical Engineering, Education Department of Guangxi Zhuang Autonomous Region, School of Intelligent Medicine and Biotechnology, Guilin Medical University, Guilin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Poly-γ-glutamic acid (γ-PGA) with different molecular weight (Mw) exhibits different properties and therefore has a variety of applications. At present, the γ-PGA is mainly produced by Methods: To address this limitation, we constructed an engineered Results: When the hydrolase genes Conclusion: In summary, an engineered strain that can dynamically regulate the γ-PGA Mw and produce γ-PGAs with specific Mws was obtained, and its regulatory range was wider than that of previous studies, which increased the application potential.

Indexed as

Bacillus subtilisdynamic regulationhydrolasemolecular weightpoly-γ-glutamic acid

Identifiers

PMID40969440
PMCPMC12442558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.